Mineralys Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-154.7M | $-177.8M | $-71.9M | $-29.8M |
| Depreciation & Amortization | $59.0K | $43.0K | $0 | — |
| Depreciation | — | — | — | — |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $19.3M | $11.3M | $5.1M | $455.0K |
| Net Cash from Operating Activities | $-142.4M | $-166.3M | $-81.2M | $-29.2M |
| Investing Activities | ||||
| Capital Expenditures | $15.0K | $96.0K | $0 | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-389.8M | $115.0M | $-160.5M | $-21.8M |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $591.0M | $116.1M | $203.2M | $128.0M |
| Net Change in Cash | $58.8M | $64.8M | $-38.4M | $77.0M |
| Free Cash Flow | $-142.4M | $-166.4M | $-81.2M | — |